Mechanisms of estrogen and antiestrogen action in mammary cancer

Benita S Katzenellenbogen, Ellen A. Rorke, Richard L. Eckert

Research output: Contribution to journalArticle

Abstract

We have evaluated the estrogen antagonist and agonist actions of antiestrogens in ovarian-dependent and autonomous rat mammary tumors, and in human MCF-7 breast cancer cells. Two of the antiestrogens (CI628 and U23,469), which we have prepared in high specific activity radiolabeled form, are metabolized during their action in vivo to demethylated forms that are preferentially localized in the nucleus and have a higher receptor affinity. Antiestrogens elicit regression of 90% of DMBA-induced tumors and during tumor regression, estrogen receptors are mainly localized in the nucleus and the level of prolactin receptors is diminished. Antiestrogens also markedly diminish the growth rate of the ovarian-autonomous but estrogen-sensitive R3230AC mammary tumor. Our studies indicate differences in the responses of tumor enzymes (glucose-6-phosphate dehydrogenase, malic enzyme, peroxidase) to estradiol and antiestrogen. Utilizing the high affinity tritium-labeled CI628 metabolite, CI628M, we find the antiestrogen-receptor complex to be similar to that of the estradiol-receptor complex in many ways, but to differ in its sedimentation properties and in its binding to DNA-cellulose. These may be suggestive of differences in chromatin interaction that may underlie the antagonist character of antiestrogens.

Original languageEnglish (US)
Pages (from-to)219-229
Number of pages11
JournalJournal of Steroid Biochemistry
Volume15
Issue numberC
DOIs
StatePublished - Dec 1981

Fingerprint

Estrogen Receptor Modulators
Estrogens
Breast Neoplasms
Tumors
Nitromifene
Estradiol Receptors
Prolactin Receptors
Estrogen Antagonists
Neoplasms
9,10-Dimethyl-1,2-benzanthracene
Tritium
Glucosephosphate Dehydrogenase
Enzymes
Metabolites
Sedimentation
Estrogen Receptors
Peroxidase
Chromatin
Rats
Estradiol

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Mechanisms of estrogen and antiestrogen action in mammary cancer. / Katzenellenbogen, Benita S; Rorke, Ellen A.; Eckert, Richard L.

In: Journal of Steroid Biochemistry, Vol. 15, No. C, 12.1981, p. 219-229.

Research output: Contribution to journalArticle

Katzenellenbogen, Benita S ; Rorke, Ellen A. ; Eckert, Richard L. / Mechanisms of estrogen and antiestrogen action in mammary cancer. In: Journal of Steroid Biochemistry. 1981 ; Vol. 15, No. C. pp. 219-229.
@article{a29c09e435104b0aad30a32963005c92,
title = "Mechanisms of estrogen and antiestrogen action in mammary cancer",
abstract = "We have evaluated the estrogen antagonist and agonist actions of antiestrogens in ovarian-dependent and autonomous rat mammary tumors, and in human MCF-7 breast cancer cells. Two of the antiestrogens (CI628 and U23,469), which we have prepared in high specific activity radiolabeled form, are metabolized during their action in vivo to demethylated forms that are preferentially localized in the nucleus and have a higher receptor affinity. Antiestrogens elicit regression of 90{\%} of DMBA-induced tumors and during tumor regression, estrogen receptors are mainly localized in the nucleus and the level of prolactin receptors is diminished. Antiestrogens also markedly diminish the growth rate of the ovarian-autonomous but estrogen-sensitive R3230AC mammary tumor. Our studies indicate differences in the responses of tumor enzymes (glucose-6-phosphate dehydrogenase, malic enzyme, peroxidase) to estradiol and antiestrogen. Utilizing the high affinity tritium-labeled CI628 metabolite, CI628M, we find the antiestrogen-receptor complex to be similar to that of the estradiol-receptor complex in many ways, but to differ in its sedimentation properties and in its binding to DNA-cellulose. These may be suggestive of differences in chromatin interaction that may underlie the antagonist character of antiestrogens.",
author = "Katzenellenbogen, {Benita S} and Rorke, {Ellen A.} and Eckert, {Richard L.}",
year = "1981",
month = "12",
doi = "10.1016/0022-4731(81)90278-8",
language = "English (US)",
volume = "15",
pages = "219--229",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "C",

}

TY - JOUR

T1 - Mechanisms of estrogen and antiestrogen action in mammary cancer

AU - Katzenellenbogen, Benita S

AU - Rorke, Ellen A.

AU - Eckert, Richard L.

PY - 1981/12

Y1 - 1981/12

N2 - We have evaluated the estrogen antagonist and agonist actions of antiestrogens in ovarian-dependent and autonomous rat mammary tumors, and in human MCF-7 breast cancer cells. Two of the antiestrogens (CI628 and U23,469), which we have prepared in high specific activity radiolabeled form, are metabolized during their action in vivo to demethylated forms that are preferentially localized in the nucleus and have a higher receptor affinity. Antiestrogens elicit regression of 90% of DMBA-induced tumors and during tumor regression, estrogen receptors are mainly localized in the nucleus and the level of prolactin receptors is diminished. Antiestrogens also markedly diminish the growth rate of the ovarian-autonomous but estrogen-sensitive R3230AC mammary tumor. Our studies indicate differences in the responses of tumor enzymes (glucose-6-phosphate dehydrogenase, malic enzyme, peroxidase) to estradiol and antiestrogen. Utilizing the high affinity tritium-labeled CI628 metabolite, CI628M, we find the antiestrogen-receptor complex to be similar to that of the estradiol-receptor complex in many ways, but to differ in its sedimentation properties and in its binding to DNA-cellulose. These may be suggestive of differences in chromatin interaction that may underlie the antagonist character of antiestrogens.

AB - We have evaluated the estrogen antagonist and agonist actions of antiestrogens in ovarian-dependent and autonomous rat mammary tumors, and in human MCF-7 breast cancer cells. Two of the antiestrogens (CI628 and U23,469), which we have prepared in high specific activity radiolabeled form, are metabolized during their action in vivo to demethylated forms that are preferentially localized in the nucleus and have a higher receptor affinity. Antiestrogens elicit regression of 90% of DMBA-induced tumors and during tumor regression, estrogen receptors are mainly localized in the nucleus and the level of prolactin receptors is diminished. Antiestrogens also markedly diminish the growth rate of the ovarian-autonomous but estrogen-sensitive R3230AC mammary tumor. Our studies indicate differences in the responses of tumor enzymes (glucose-6-phosphate dehydrogenase, malic enzyme, peroxidase) to estradiol and antiestrogen. Utilizing the high affinity tritium-labeled CI628 metabolite, CI628M, we find the antiestrogen-receptor complex to be similar to that of the estradiol-receptor complex in many ways, but to differ in its sedimentation properties and in its binding to DNA-cellulose. These may be suggestive of differences in chromatin interaction that may underlie the antagonist character of antiestrogens.

UR - http://www.scopus.com/inward/record.url?scp=0019725641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019725641&partnerID=8YFLogxK

U2 - 10.1016/0022-4731(81)90278-8

DO - 10.1016/0022-4731(81)90278-8

M3 - Article

C2 - 7339248

AN - SCOPUS:0019725641

VL - 15

SP - 219

EP - 229

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - C

ER -